-
Progress of ctDNA in predicting prognosis of patients with urological tumors
Circulating tumor DNA (ctDNA) for predicting tumor prognosis and guiding individualized treatment is a hot topic in malignant tumor research. ctDNA exists in the peripheral blood of tumor patients in a cell-free state and can dynamically evaluate the tumor condition, overcoming tumor heterogeneity biases. The 2023 American Association for Cancer Research (AACR) Annual Meeting was…
-
New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC
According to results from the phase 1a/1b LOXO-RAS-20001 study (NCT04956640) showcased at the 2023 American Association for Cancer Research (AACR) annual meeting, the KRAS G12C inhibitor LY3537982 exhibited clinical efficacy in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors.
-
Application of high-throughput next-generation sequencing in diagnosis and treatment of myeloid hematologic malignancies in the era of precision medic
In May 2023, Professor Jun Ma and his team from Harbin Institute of Hematology Oncology published a paper in the Journal of Leukemia & Lymphoma titled “Application of high-throughput next-generation…
-
Exploring New Breast Cancer Risk Genes, Biomarkers, and Prognostic Models at AACR 2023
The American Association for Cancer Research (AACR) held its annual conference from April 14th to 19th, 2023 in Orlando, USA. With numerous reports on clinical, fundamental, and translational cancer research presented each year, this year’s AACR conference delved deep into the realm of breast cancer. Research focused on the analysis of various susceptibility genes and…
-
Efficacy & safety of Mitoxantrone Liposome in treating peripheral T-cell lymphomas: A real-world study (MOMENT)
Efficacy and safety of mitoxantrone hydrochloride liposome injection in treatment of peripheral T-cell lymphomas: a multicenter, non-interventional, ambispective cohort, real-world study (MOMENT) In August 2023, Professor Jun Ma and his…
-
Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies
The 2023 American Association for Cancer Research (AACR) Annual Meeting was held in Orlando, USA, from April 14 to 19, 2023. Every year, the AACR Congress reports numerous clinical, basic, and translational studies on cancer, especially innovative therapies in the preliminary phase I/II research stages. At this year’s AACR conference, three clinical trials were reported…
-
Dr. Lu Si: mRNA Vaccines and TIGIT Monoclonal Antibodies — New Stars of 2023 AACR
PD-1 inhibitors have become the international standard for adjuvant treatment of stage IIB-IV melanoma after surgery. Research on the neoadjuvant use of PD-1 monotherapy (pembrolizumab) for resectable melanoma was just published in the New England Journal of Medicine in March of this year. With this, PD-1 inhibitors cover the two major treatment areas of neoadjuvant…
-
🩸🇨🇳💡Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A national multicenter survey research
Professor Jun Ma and his team from Harbin Institute of Hematology Oncology published in May 2023 in the Chinese Journal of Hematology titled “Current status of diagnosis and treatment of…
Connecting Medical Expertise through Media